India's National Pharmaceutical Pricing Authority (NPPA) is directing certain companies to ensure the availability of critical medicines, and exempting a "novel" oncology formulation from price control, reported The Economic Times.
The regulator asked companies including Abbott, Bayer and Sanofi to not discontinue critical medicines for malaria, leprosy and arrhythmias without prior notice to prevent shortages in the country.
Abbott had sought approval to discontinue the leprosy drug Hansepran, while Bayer had done the same for the malaria treatment Resochin, and Sanofi for the cardiac drug Adenocor, sources said.
Fearing that a sudden discontinuation could lead to drug shortages, the NPPA has asked the companies to issue a public notice, and continue their production, import and sale for 12 months after that.
The agency has also exempted Sun Pharmaceutical's ready-to-use infusion bags of gemcitabine from price control, as it is helpful in administration to patients.